No profile data available.
HTG Molecular Diagnostics, Inc. (HTGMQ) is a healthcare company in the additional medical testing equipment industry, based in Tucson, United States, with about 53 full-time employees.
It reported revenue of $6.37 million for fiscal year 2022, down 28.5% from fiscal year 2021, and net income of -$21.59 million. In Q1 2023 (the quarter ended March 31, 2023) revenue was $1.03 million, down 12.8% from a year before. Its market capitalization was $221 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2022; market data as of October 8, 2026.
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets.
HTG Molecular Diagnostics reported $6.37 million in revenue for fiscal year 2022, down 28.5% from $8.91 million in fiscal year 2021. In Q1 2023 revenue was $1.03 million.
$221 as of October 8, 2026.
Listed companies of a similar size in the same industry (additional medical testing equipment) include Response Genetics, Inc (RGDXQ), Rosetta Genomics Ltd. (ROSGQ), Biocept, Inc. (BIOCQ), Optigenex Inc. (OPGX).